SK Chemicals’ domestic hemophilia treatment enters U.S. market
On the 27th, SK Chemicals(CEO Man-hoon Park) announced the final commercialization approval of ‘NBP601,’ a hemophilia treatment, from the U.S. Food and Drug Administration(FDA).
NBP601 is the first drug which acquired the FDA’s commercialization approval as a new biopharmaceutical drug develope...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
